"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Mozobil Patient Information including How Should I Take
In this Article
- What is plerixafor (Mozobil)?
- What are the possible side effects of plerixafor (Mozobil)?
- What is the most important information I should know about plerixafor (Mozobil)?
- What should I discuss with my health care provider before receiving plerixafor (Mozobil)?
- How is plerixafor given (Mozobil)?
- What happens if I miss a dose (Mozobil)?
- What happens if I overdose (Mozobil)?
- What should I avoid while receiving plerixafor (Mozobil)?
- What other drugs will affect plerixafor (Mozobil)?
- Where can I get more information?
What should I discuss with my health care provider before receiving plerixafor (Mozobil)?
You should not receive this medication if you are allergic to plerixafor, or if you have leukemia.
To make sure you can safely use plerixafor, tell your doctor if you have kidney disease.
FDA pregnancy category D. Do not receive plerixafor if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment.
It is not known whether plerixafor passes into breast milk or if it could harm a nursing baby. You should not breast-feed while receiving this medication.
How is plerixafor given (Mozobil)?
Plerixafor is injected under the skin. You will receive this injection in a hospital or clinic setting.
Before receiving plerixafor, you will be given a medication called a granulocyte (GRAN-yoo-loe-site) colony stimulating factor, also called G-CSF. Some examples of a G-CSF are filgrastim (Neupogen), pegfilgrastim (Neulasta), and sargramostim (Leukine).
A G-CSF will cause your bone marrow to produce stem cells and certain white blood cells called granulocytes, which help support your immune system.
Plerixafor works together with the G-CSF by causing stem cells and granulocytes produced in the bone marrow to circulate into your blood stream where they can be collected in blood drawn from your vein.
After your blood is drawn, it will be processed so that the needed stem cells and granulocytes can be separated from other unneeded parts of the blood. These stem cells and granulocytes will then be "transplanted" back into your vein through an IV injection.
To be sure plerixafor is not causing harmful effects, your blood will need to be tested often during your treatment.
Additional Mozobil Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.